Pathogenic variants of sphingomyelin synthase SMS2 disrupt lipid landscapes in the secretory pathway

  1. Tolulope Sokoya
  2. Jan Parolek
  3. Mads Møller Foged
  4. Dmytro I Danylchuk
  5. Manuel Bozan
  6. Bingshati Sarkar
  7. Angelika Hilderink
  8. Michael Philippi
  9. Lorenzo D Botto
  10. Paulien A Terhal
  11. Outi Mäkitie
  12. Jacob Piehler
  13. Yeongho Kim
  14. Christopher G Burd
  15. Andrey S Klymchenko
  16. Kenji Maeda
  17. Joost CM Holthuis  Is a corresponding author
  1. Osnabrück University, Germany
  2. Danish Cancer Society, Denmark
  3. Université de Strasbourg, UMR 7021, CNRS, France
  4. University of Utah, United States
  5. Utrecht University, Netherlands
  6. University of Helsinki, Finland
  7. Yale University, United States

Abstract

Sphingomyelin is a dominant sphingolipid in mammalian cells. Its production in the trans-Golgi traps cholesterol synthesized in the ER to promote formation of a sphingomyelin/sterol gradient along the secretory pathway. This gradient marks a fundamental transition in physical membrane properties that help specify organelle identify and function. We previously identified mutations in sphingomyelin synthase SMS2 that cause osteoporosis and skeletal dysplasia. Here we show that SMS2 variants linked to the most severe bone phenotypes retain full enzymatic activity but fail to leave the ER owing to a defective autonomous ER export signal. Cells harboring pathogenic SMS2 variants accumulate sphingomyelin in the ER and display a disrupted transbilayer sphingomyelin asymmetry. These aberrant sphingomyelin distributions also occur in patient-derived fibroblasts and are accompanied by imbalances in cholesterol organization, glycerophospholipid profiles and lipid order in the secretory pathway. We postulate that pathogenic SMS2 variants undermine the capacity of osteogenic cells to uphold nonrandom lipid distributions that are critical for their bone forming activity.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file. Source Data files have been provided for Figures 2-4, 7-9 and Appendix 1 - figure 3.

Article and author information

Author details

  1. Tolulope Sokoya

    Department of Biology and Center of Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Jan Parolek

    Department of Biology and Center of Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Mads Møller Foged

    Center for Autophagy, Recycling and Disease, Danish Cancer Society, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  4. Dmytro I Danylchuk

    Laboratoire de Bioimagerie et Pathologies, Université de Strasbourg, UMR 7021, CNRS, Strasbourg, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Manuel Bozan

    Department of Biology and Center of Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8426-369X
  6. Bingshati Sarkar

    Department of Biology and Center of Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Angelika Hilderink

    Department of Biology and Center of Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Michael Philippi

    Department of Biology and Center of Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Lorenzo D Botto

    Department of Pediatrics, University of Utah, Salt Lake City, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Paulien A Terhal

    Department of Genetics, Utrecht University, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  11. Outi Mäkitie

    Children's Hospital, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4547-001X
  12. Jacob Piehler

    Department of Biology and Center of Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2143-2270
  13. Yeongho Kim

    Department of Cell Biology, Yale University, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1477-925X
  14. Christopher G Burd

    Department of Cell Biology, Yale University, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1831-8706
  15. Andrey S Klymchenko

    Laboratoire de Bioimagerie et Pathologies, Université de Strasbourg, UMR 7021, CNRS, Strasbourg, France
    Competing interests
    The authors declare that no competing interests exist.
  16. Kenji Maeda

    Center for Autophagy, Recycling and Disease, Danish Cancer Society, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  17. Joost CM Holthuis

    Department of Biology and Center of Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany
    For correspondence
    jholthuis@uni-osnabrueck.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8912-1586

Funding

Deutsche Forschungsgemeinschaft (SFB944-P14)

  • Joost CM Holthuis

Deutsche Forschungsgemeinschaft (HO3539/1-1)

  • Joost CM Holthuis

Deutsche Forschungsgemeinschaft (SFB944-P8)

  • Jacob Piehler

National Institutes of Health (R35 GM144096)

  • Christopher G Burd

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Sokoya et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,418
    views
  • 533
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Tolulope Sokoya
  2. Jan Parolek
  3. Mads Møller Foged
  4. Dmytro I Danylchuk
  5. Manuel Bozan
  6. Bingshati Sarkar
  7. Angelika Hilderink
  8. Michael Philippi
  9. Lorenzo D Botto
  10. Paulien A Terhal
  11. Outi Mäkitie
  12. Jacob Piehler
  13. Yeongho Kim
  14. Christopher G Burd
  15. Andrey S Klymchenko
  16. Kenji Maeda
  17. Joost CM Holthuis
(2022)
Pathogenic variants of sphingomyelin synthase SMS2 disrupt lipid landscapes in the secretory pathway
eLife 11:e79278.
https://doi.org/10.7554/eLife.79278

Share this article

https://doi.org/10.7554/eLife.79278

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.